Tags

Type your tag names separated by a space and hit enter

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Fertil Steril. 2016 Feb; 105(2):356-63.FS

Abstract

OBJECTIVE

To determine the optimal GnRH agonist dose for triggering of oocyte maturation in oocyte donors.

DESIGN

Single-center, randomized, parallel, investigator-blinded trial.

SETTING

IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.

PATIENT(S)

One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] <28 kg/m(2), antimüllerian hormone level >1.25 ng/mL, and antral follicle count ≥6).

INTERVENTION(S)

Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.

MAIN OUTCOME MEASURE(S)

The primary end point was number of metaphase II oocytes. Secondary end points were fertilization and cleavage rates, number of embryos and top-quality embryos, steroid levels, ovarian volume, and ongoing pregnancy rate (PR) in recipients.

RESULT(S)

There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0). Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively. Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 ng/ml) versus 0.2 mg (1.1 ± 1.0 ng/ml) and 0.3 mg (1.2 ± 1.6 ng/ml). One patient developed early-onset severe ovarian hyperstimulation syndrome (OHSS).

CONCLUSION(S)

No significant differences between triptorelin doses of 0.2, 0.3, and 0.4 mg used for ovulation trigger in oocyte donors were seen with regard to the number of mature oocytes and top-quality embryos.

CLINICAL TRIAL REGISTRATION NUMBER

NCT02208986.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy HCMC, Ho Chi Minh City, Vietnam; IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. Electronic address: drlan@yahoo.com.vn.IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam; Research Center for Genetics and Reproductive Health (CGRH), School of Medicine, Vietnam National University HCMC, Ho Chi Minh City, Vietnam.National Hospital of Can Tho, Ho Chi Minh City, Vietnam; Ton Duc Thang University, Ho Chi Minh City, Vietnam.IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.The Fertility Clinic, Skive Regional Hospital, Aarhus, Denmark; Faculty of Health, Aarhus University and Faculty of Health, University of Southern Denmark, Aarhus, Denmark.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26523330

Citation

Vuong, Thi Ngoc Lan, et al. "Gonadotropin-releasing Hormone Agonist Trigger in Oocyte Donors Co-treated With a Gonadotropin-releasing Hormone Antagonist: a Dose-finding Study." Fertility and Sterility, vol. 105, no. 2, 2016, pp. 356-63.
Vuong TN, Ho MT, Ha TD, et al. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016;105(2):356-63.
Vuong, T. N., Ho, M. T., Ha, T. D., Phung, H. T., Huynh, G. B., & Humaidan, P. (2016). Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertility and Sterility, 105(2), 356-63. https://doi.org/10.1016/j.fertnstert.2015.10.014
Vuong TN, et al. Gonadotropin-releasing Hormone Agonist Trigger in Oocyte Donors Co-treated With a Gonadotropin-releasing Hormone Antagonist: a Dose-finding Study. Fertil Steril. 2016;105(2):356-63. PubMed PMID: 26523330.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. AU - Vuong,Thi Ngoc Lan, AU - Ho,Manh Tuong, AU - Ha,Tan Duc, AU - Phung,Huy Tuan, AU - Huynh,Gia Bao, AU - Humaidan,Peter, Y1 - 2015/10/31/ PY - 2015/08/19/received PY - 2015/10/07/revised PY - 2015/10/13/accepted PY - 2015/11/3/entrez PY - 2015/11/3/pubmed PY - 2016/6/30/medline KW - In vitro fertilization KW - dose-finding KW - gonadotropin-releasing hormone agonist trigger KW - oocyte donor KW - triptorelin SP - 356 EP - 63 JF - Fertility and sterility JO - Fertil. Steril. VL - 105 IS - 2 N2 - OBJECTIVE: To determine the optimal GnRH agonist dose for triggering of oocyte maturation in oocyte donors. DESIGN: Single-center, randomized, parallel, investigator-blinded trial. SETTING: IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. PATIENT(S): One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] <28 kg/m(2), antimüllerian hormone level >1.25 ng/mL, and antral follicle count ≥6). INTERVENTION(S): Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle. MAIN OUTCOME MEASURE(S): The primary end point was number of metaphase II oocytes. Secondary end points were fertilization and cleavage rates, number of embryos and top-quality embryos, steroid levels, ovarian volume, and ongoing pregnancy rate (PR) in recipients. RESULT(S): There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0). Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively. Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 ng/ml) versus 0.2 mg (1.1 ± 1.0 ng/ml) and 0.3 mg (1.2 ± 1.6 ng/ml). One patient developed early-onset severe ovarian hyperstimulation syndrome (OHSS). CONCLUSION(S): No significant differences between triptorelin doses of 0.2, 0.3, and 0.4 mg used for ovulation trigger in oocyte donors were seen with regard to the number of mature oocytes and top-quality embryos. CLINICAL TRIAL REGISTRATION NUMBER: NCT02208986. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/26523330/Gonadotropin_releasing_hormone_agonist_trigger_in_oocyte_donors_co_treated_with_a_gonadotropin_releasing_hormone_antagonist:_a_dose_finding_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(15)02021-X DB - PRIME DP - Unbound Medicine ER -